Skip to main content
. 2017 Jul 19;8(35):58847–58864. doi: 10.18632/oncotarget.19375

Figure 7. In vitro and in vivo characterization of lapatinib resistance in 78617/LR cells.

Figure 7

(A) Survival fraction of 78617 and 78617/LR cells after lapatinib treatment for 5 days was examined by an MTS assay. (B) RTK and CIP2A expression and/or activity levels in 78617 and 78617/LR cells treated with lapatinib for 24 hours were detected by Western blotting. 78617 and 78617/LR cells were inoculated in the flanks of MMTV-ErbB2 transgenic mice for syngeneic tumor transplantation experiments. Approximately 6 days after tumor cell inoculations, palpable tumors were formed and lapatinib (75 mg/kg BW twice daily via oral gavage) treatments began. Tumor growth was monitored every 2 days and tumor dimensions were recorded. Tumor volumes throughout the duration of lapatinib treatments are graphed in (C). After 12 days of lapatinib treatment, tumors were excised and weighed. The average tumor weights are graphed in (D). (E) Total protein was extracted from collected tumors after 4 days of lapatinib treatments and Western blotting was performed to detect CIP2A levels and Akt activation and expression. All values are presented as the mean ± S.E. (**p < 0.01).